Altimmune(ALT)
搜索文档
Altimmune(ALT) - 2024 Q3 - Quarterly Report
2024-11-13 05:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMMUNE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2726770 (State or ...
Altimmune(ALT) - 2024 Q3 - Earnings Call Transcript
2024-11-12 23:00
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Ray Jordt - Chief Business Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore William Wood - B. Riley Securities Operator Good day, ladies and gentlemen, and welcome to ...
Altimmune(ALT) - 2024 Q3 - Quarterly Results
2024-11-12 20:09
Exhibit 99.1 Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-t ...
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2024-11-11 20:30
核心观点 - Altimmune公司董事会薪酬委员会授予Gregory Weaver股权奖励以聘请其为首席财务官[1] 关于授予股权奖励 - Gregory Weaver共获得购买225000股Altimmune普通股的期权和75000个受限股票单位(RSUs)期权行使价格等于2024年11月11日(授予日)Altimmune普通股的收盘价四分之一的期权所涉及的股票将在授予日的一周年纪念日归属之后每月将有1/36的期权所涉及的股票归属这样期权所涉及的股票将在授予日的四周年纪念日完全归属前提是Weaver先生在这些归属日期继续受雇于Altimmune[2] - 根据2024年11月8日Altimmune普通股的收盘价Altimmune将根据其2018年诱导性授予计划发行约172920个期权作为诱导奖励其余作为其2017年综合激励计划下的激励性股票期权2018年诱导性授予计划和2017年综合计划之间期权的最终分配将根据授予日Altimmune普通股的收盘价进行调整[2] - 四分之一的RSUs将在授予日的一周年纪念日归属之后RSUs将分三个大致相等的年度分期付款归属这样RSUs将在授予日的四周年纪念日完全归属前提是Weaver先生在这些归属日期继续受雇于Altimmune[3] 关于Altimmune公司 - Altimmune是一家临床阶段的生物制药公司专注于开发创新的下一代基于肽的疗法该公司正在开发pemvidutide一种GLP - 1/胰高血糖素双受体激动剂用于治疗肥胖症和MASH[4]
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
GlobeNewswire News Room· 2024-11-11 20:30
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including SEC reporting and investor relations. “We are pleased to welcome Greg to Altimmune’s executive team during such a pivotal time in our evolution. He has a wealth of experience that we believe will be in ...
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
MarketBeat· 2024-11-08 20:46
As pharma giants Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO are raking in the cash from their weight loss and diabetes drugs, many other companies want a piece of the pie. They’re developing treatments to improve upon the deficiencies of Lilly and Novo’s drugs. Altimmune TodayALTAltimmune$7.46 +0.15 (+2.05%) 52-Week Range$2.32▼$14.84Price Target$18.80Add to WatchlistOne company to keep an eye on in this space is Altimmune NASDAQ: ALT. But what makes Altimmune's drug different from existing drugs, and w ...
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
GlobeNewswire News Room· 2024-11-04 20:30
GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.alti ...
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
GlobeNewswire News Room· 2024-10-01 19:30
GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference: Conference:H.C. Wainwright 8thAnnual MASH Virtual Conference Presenters:Vipin Garg, Ph.D., Chief Executive Officer Scott Harris, M.D., Chief Medical Officer Date/Time:Mond ...
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
GlobeNewswire News Room· 2024-09-30 19:30
IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program with U.S. Food and Drug Administration (FDA) has been scheduled for early November 2024 Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning in Q4 2024 GAITHERSBURG, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), ...
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Seeking Alpha· 2024-09-21 17:21
文章核心观点 - 该研究分析师专注于医疗保健行业,擅长发现创新公司和潜在收购目标 [1] - 该分析师在Seeking Alpha上发表了关于Altimmune公司的研究文章,认为其主要候选药物pemvidutide有望在肥胖市场占据重要地位 [1] - 该分析师拥有10年投资银行从业经验,专注于行业和公司研究,擅长解读各种信息发现投资机会和风险 [1] 公司相关 - Altimmune公司是该分析师关注的一家公司,其主要候选药物pemvidutide有望在肥胖市场占据重要地位 [1] - 该分析师之前发表过关于Altimmune公司的研究文章 [1] 行业相关 - 该分析师专注于医疗保健行业,擅长发现创新公司和潜在收购目标 [1]